Ratings Zhejiang CONBA Pharmaceutical Co.,Ltd.

Equities

600572

CNE000001H86

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
5.22 ^CNY	+2.15%		-1.32%	+3.37%

Apr. 26	Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 19	Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 47% by 2026.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.	+3.37%	1.83B		C+
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.04%	42.95B		B-
OTSUKA HOLDINGS CO., LTD.	+16.92%	21.38B		B+
SANDOZ GROUP AG	+18.33%	15.05B		-
CIPLA LIMITED	+19.27%	14.45B		B+
ZYDUS LIFESCIENCES LIMITED	+56.12%	13.04B		B
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
ONO PHARMACEUTICAL CO., LTD.	-10.73%	6.72B		B+
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes